Comparative Pharmacology
Head-to-head clinical analysis: SEROSTIM versus SEROSTIM LQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SEROSTIM versus SEROSTIM LQ.
SEROSTIM vs SEROSTIM LQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SEROSTIM is a recombinant human growth hormone that binds to growth hormone receptors, activating JAK2/STAT5 signaling pathways, leading to increased production of insulin-like growth factor 1 (IGF-1). It promotes linear growth, protein synthesis, and lipolysis.
Recombinant human growth hormone (somatropin) that binds to growth hormone receptors, activating JAK-STAT signaling pathways, leading to increased insulin-like growth factor-1 (IGF-1) production, which promotes linear growth and anabolic effects.
0.1 mg/kg subcutaneously once daily for 4 weeks; alternatively, 4 mg subcutaneously once daily for 4 weeks for patients ≥35 kg.
0.2 mg/kg subcutaneously once daily for 4 weeks in HIV-associated wasting; for growth hormone deficiency, 0.005 mg/kg subcutaneously once daily initially, titrated to 0.01 mg/kg once daily.
None Documented
None Documented
Terminal half-life of approximately 2-3 hours after subcutaneous administration; prolonged in renal impairment (up to 6-8 hours).
2.6 hours (subcutaneous administration); terminal half-life is approximately 2-3 hours, requiring daily dosing for growth hormone deficiency.
Primarily renal (90% metabolized in liver and kidneys; 0.1% excreted unchanged in urine); biliary/fecal negligible.
Renal: >90% of somatropin is metabolized in the liver and kidneys; less than 1% of the administered dose is excreted unchanged in urine.
Category C
Category C
Growth Hormone
Growth Hormone